Relx Technology, one of China’s biggest e-cigarette producer accounting for 68.8% of the total domestic market share, has unveiled a new bioscience lab in Shenzhen to study the health effects of vaping and gather scientific evidence to prove that e-cigarettes are a safe alternative to smoking.
The lab will investigate short- and long-term behavioral impacts of e-cigarettes compared to traditional cigarettes using 3D printed models of human lungs. It will also examine the impact of Relx products on animal cardiovascular, respiratory and nervous systems by testing them on mice.
“E-cigarettes are sometimes viewed with suspicion because we have incomplete knowledge," said Wen Yilong, Relx co-founder and head of r&d and supply chain.
"Relx bioscience lab’s mission is to explore the unknown. We want to collect evidence through a scientific approach and strive to prove the potential for e-cigarettes to be less harmful, and in doing so, provide users with the option to choose an alternative.”
“As an innovative product, it’s inevitable that e-cigarettes face many doubts from the start. Many characteristics haven’t been answered scientifically, and that’s why we decided to advance to science.”
Relx is currently collaborating with six Chinese universities including the Sun Yat-sen University and Shenzhen Institutes of Advanced Technology, as well as two hospitals and nine scientific research institutions, and plans to partner with more universities and scientific institutions in the next 10 years, and open more labs to study the long-term effects of vaping.